Pharmaceutical Investment Oversight and Accountability Act
- Sponsor
- Sen. Warren, Elizabeth [D-MA]
- Committees
- Banking, Housing, and Urban Affairs Committee (primary)
- Last action
- Jul 15, 2026
Bottom line
The bill establishes an annual reporting requirement for the FTC and CFIUS to monitor and assess the effects of foreign investment on the security and capacity of the U.S. pharmaceutical and biotechnology industries.
What it actually does
This bill mandates the Federal Trade Commission (FTC), in consultation with the Committee on Foreign Investment in the United States (CFIUS), to submit annual reports on foreign investment in the U.S. pharmaceutical industry. These reports must assess the impact of foreign investment on the pharmaceutical supply chain, domestic drug manufacturing capacity, and investment in DNA sequencing and storage technologies. It also requires reporting on the number and description of CFIUS reviews and investigations related to these sectors.
Proponents argue
Supporters argue this bill enhances national security and public health by providing critical transparency into foreign influence over essential pharmaceutical and biotechnological capabilities. This regular reporting will allow policymakers to identify vulnerabilities in the supply chain, assess domestic production capacity, and take proactive measures to protect against foreign control of vital health infrastructure and sensitive data.
Opponents contend
Critics might contend that this bill could create unnecessary bureaucratic burdens for the FTC and CFIUS, potentially deterring beneficial foreign investment that could otherwise bring capital, innovation, and jobs to the U.S. pharmaceutical and biotechnology industries. They might also argue that existing CFIUS processes are already sufficient for addressing national security concerns related to foreign investment.
The bill is very short and straightforward, making it highly accessible for any reader to understand its core purpose quickly.
Section 2(a) and 2(b)
Oversight of Foreign Pharmaceutical Investment Report Mandate
This provision requires the Federal Trade Commission (FTC), in consultation with the Committee on Foreign Investment in the United States (CFIUS), to produce an annual report. This report must analyze foreign investment in the U.S. pharmaceutical industry, assessing its impact on the supply chain, domestic drug manufacturing capacity (including active and inactive ingredients), and investment in DNA sequencing and storage technologies. It also requires the report to detail the number and nature of CFIUS reviews and investigations in these areas over the preceding 10 fiscal years.
Supporters argue
Supporters argue this provision is crucial for identifying and mitigating risks associated with foreign control over vital pharmaceutical production and sensitive biotechnologies, thereby safeguarding national security and public health by ensuring a resilient domestic supply chain.
Critics contend
Critics might argue that this provision could lead to excessive government oversight, potentially discouraging foreign investment that could otherwise benefit the U.S. pharmaceutical and biotechnology sectors through capital infusion, innovation, and job creation.
Tradeoffs
This provision balances the need for transparency and national security oversight in critical industries against the potential for deterring beneficial foreign investment and increasing administrative burdens on federal agencies.
Section 2(c) and 2(d)
FTC Authority and Public Publication of Report Summary
This provision explicitly grants the Federal Trade Commission the necessary authority under section 6 of the Federal Trade Commission Act to conduct the studies required for the annual report. Furthermore, it mandates that an unclassified summary of the report be published on a publicly available internet website of the Commission, ensuring public access to the key findings.
The report's scope includes foreign investment in "technologies or other products for sequencing or storage of DNA, including genome and exome analysis" in the United States.
Section 2(b)(1)(C)
Why it matters:This is standard legislative practice to comprehensively define the scope of a report. It is not evasive, but rather ensures a thorough assessment of related critical technologies.
Case for: Proponents argue that including DNA sequencing and storage is vital for national security, given the strategic importance of genomic data, the rapid advancements in biotechnology, and the potential for foreign adversaries to gain access or control over critical biotechnological infrastructure and sensitive health data.
Case against: Critics might argue that this broad inclusion could extend the FTC's and CFIUS's oversight into areas that are not directly related to drug manufacturing, potentially overreaching and creating additional regulatory hurdles for a rapidly evolving and innovative sector, which could inadvertently slow down scientific progress.
Estimated impact: Expands the scope of foreign investment scrutiny beyond traditional pharmaceuticals into the broader biotechnology and data infrastructure relevant to genomics, potentially affecting investment flows and regulatory considerations in these high-tech areas.